GINKGO BIOWORKS HOLDINGS
NYSE: DNA (Ginkgo Bioworks Holdings, Inc.)
Last update: yesterday, 11:20AM8.03
0.08 (1.01%)
| Previous Close | 7.95 |
| Open | 8.29 |
| Volume | 1,598,252 |
| Avg. Volume (3M) | 1,189,459 |
| Market Cap | 497,252,544 |
| Price / Sales | 2.18 |
| Price / Book | 0.810 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -198.84% |
| Operating Margin (TTM) | -182.09% |
| Diluted EPS (TTM) | -8.91 |
| Quarterly Revenue Growth (YOY) | 27.30% |
| Total Debt/Equity (MRQ) | 67.12% |
| Current Ratio (MRQ) | 4.88 |
| Operating Cash Flow (TTM) | -281.85 M |
| Levered Free Cash Flow (TTM) | -185.65 M |
| Return on Assets (TTM) | -16.99% |
| Return on Equity (TTM) | -57.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ginkgo Bioworks Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.20 |
|
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.88% |
| % Held by Institutions | 77.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 31 Dec 2025 | 2,000,000 |
| Anchorage Capital Group, L.L.C. | 31 Dec 2025 | 1,746,363 |
| Forbes J M & Co Llp | 31 Mar 2026 | 1,028,391 |
| Prescott Group Capital Management, L.L.C. | 31 Dec 2025 | 541,845 |
| 52 Weeks Range | ||
| Median | 5.00 (-37.73%) | |
| Total | 1 Sell | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 12 Mar 2026 | 5.00 (-37.73%) | Sell | 6.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CANTON BARRY | - | 6.59 | -150,998 | -979,331 |
| KELLY JASON R | - | 6.66 | -206,782 | -1,373,265 |
| SHETTY RESHMA P. | - | 6.59 | -150,998 | -979,331 |
| Aggregate Net Quantity | -508,778 | |||
| Aggregate Net Value ($) | -3,331,928 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 6.60 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SHETTY RESHMA P. | Officer | 10 Apr 2026 | Sell (-) | 124,727 | 6.45 | 804,489 |
| CANTON BARRY | 10 Apr 2026 | Sell (-) | 124,727 | 6.45 | 804,489 | |
| KELLY JASON R | Officer | 09 Apr 2026 | Sell (-) | 109,767 | 6.43 | 705,802 |
| CANTON BARRY | 09 Apr 2026 | Sell (-) | 13,116 | 6.43 | 84,336 | |
| SHETTY RESHMA P. | Officer | 09 Apr 2026 | Sell (-) | 13,116 | 6.43 | 84,336 |
| SHETTY RESHMA P. | Officer | 09 Apr 2026 | Option execute | 251,786 | - | - |
| CANTON BARRY | 09 Apr 2026 | Option execute | 251,786 | - | - | |
| KELLY JASON R | Officer | 08 Apr 2026 | Sell (-) | 97,015 | 6.88 | 667,463 |
| KELLY JASON R | Officer | 08 Apr 2026 | Option execute | 212,949 | - | - |
| CANTON BARRY | 08 Apr 2026 | Sell (-) | 13,155 | 6.88 | 90,506 | |
| CANTON BARRY | 08 Apr 2026 | Option execute | 27,738 | - | - | |
| SHETTY RESHMA P. | Officer | 08 Apr 2026 | Sell (-) | 13,155 | 6.88 | 90,506 |
| SHETTY RESHMA P. | Officer | 08 Apr 2026 | Option execute | 27,738 | - | - |
| KELLY JASON R | Officer | 07 Apr 2026 | Option execute | 212,949 | - | - |
| CANTON BARRY | 07 Apr 2026 | Option execute | 27,738 | - | - | |
| SHETTY RESHMA P. | Officer | 07 Apr 2026 | Option execute | 27,738 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |